# **Special Issue**

# **CNS Drugs Delivery**

## Message from the Guest Editors

The blood-brain barrier (BBB), the blood-central system fluid (CSF) barrier (BCB), and the blood-tumor barrier (BTB) are major hurdles in treating central nervous system (CNS) diseases of the brain and spine, as they limit the passage of most therapeutic agents from the blood into CNS tissues. Currently, there is no standard treatment approach for penetrating/bypassing these barriers. The increasing worldwide lifespan has led to a rise in the prevalence of neurodegenerative disorders, which now have a huge impact on society and the economy. However, the majority of currently available treatments are ineffective due to the low or zero penetration of most therapeutic agents through the CNS barriers. Thus, means to bypass these barriers, or transiently disrupt them in a safe and controlled manner, are desperately needed. This Special Issue describes the current strategies used for CNS drug delivery.

### **Guest Editors**

Prof. Dr. Yael Mardor

- 1. The Advanced Technology Center, Sheba Medical Center, Ramat Gan 52621, Israel
- 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

Dr. Shirley Sharabi

The Advanced Technology Center, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel

### Deadline for manuscript submissions

closed (25 August 2023)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



## mdpi.com/si/131701

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

